hVIVO (LON:HVO) Shares Up 23% - Time to Buy?

hVIVO plc (LON:HVO - Get Free Report)'s stock price was up 23% during mid-day trading on Monday . The stock traded as high as GBX 11 ($0.15) and last traded at GBX 10.70 ($0.15). Approximately 24,253,932 shares changed hands during trading, an increase of 569% from the average daily volume of 3,624,890 shares. The stock had previously closed at GBX 8.70 ($0.12).

Analysts Set New Price Targets

Separately, Shore Capital restated a "buy" rating on shares of hVIVO in a research report on Friday, May 30th.

hVIVO Stock Performance

The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The business has a 50-day moving average price of GBX 15.92 and a 200 day moving average price of GBX 17.70. The stock has a market capitalization of £74.98 million, a P/E ratio of 4.37 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings data on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, sell-side analysts forecast that hVIVO plc will post 1.5492958 EPS for the current fiscal year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.